StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Wednesday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 5.4 %

Shares of NYSE BTX opened at $0.29 on Wednesday. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10. The business has a fifty day simple moving average of $0.58 and a 200 day simple moving average of $1.23. The firm has a market capitalization of $17.29 million, a price-to-earnings ratio of -0.13 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.